Get In Touch

Tetracycline drugs are a class of antibacterial drugs that are responsible for the inhibition of bacterial protein synthesis. These are derived from various strains of Streptomyces bacteria. The molecules of the drug irreversibly bind to the 30S ribosomal subunit, and thus inhibit the elongation step of the bacterial protein synthesis. Tetracyclines are present in both forms i.e., lyophilic and hydrophilic, which gives them access to both gram positive as well as gram negative forms of bacterial strains. A few gram negative bacterial strains possess natural resistance to these tetracyclines such as Proteus mirabilis, which renders these drugs ineffective against such strains, but no resistance has been observed in gram positive strains. 

Key drivers of tetracycline drugs include increase in prevalence of various bacterial infections across the world and persistent demand for these drugs among patients and health care professionals. Additionally, availability of large number of generics make these drugs more affordable in the emerging economies, which in turn increases demand in these markets. Governments across the world have taken initiatives to incentivize innovation in the field of tetracycline drugs in order to address the urgent need of better treatment for bacterial infections and to combat rapid development of antibiotic-resistant species. Leading tetracycline generic drugs available in the market include doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, bedaquiline, and tigecycline. However, availability of several alternative antibacterial drugs and small number of novel drugs in the segment restrain the market. The global tetracycline drugs market can be segmented based on application, distribution channel, and region. In terms of application, the market can be categorized into respiratory, bowel, genital, local, and systemic infections. Based on distribution channel, the global tetracycline drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the global tetracycline drugs market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. Asia Pacific was the largest market for tetracycline drugs in 2016. The region is projected to continue to dominate the market in terms of revenue during the forecast period. Growth of the market in the region is expected to be propelled by increase in number of pharmaceutical manufacturers and presence of generics manufacturers. Moreover, rise in incidence of bacterial infections such as MRSA infections and Clostridium difficile, and growing patient awareness are the other factors likely to drive the market in Asia Pacific.

North America was identified as the second largest market in 2016 and is expected to witness strong growth during the forecast period. The U.S. Senate passed the Generating Antibiotic Incentives Now (GAIN) Act to promote innovation in discovery of novel antibacterial drugs. Various drugs have received Qualified Infectious Disease Product (QIDP) designation since the implementation of the act, which provides drug manufacturers with the following incentives: drugs with QIDP designation enjoy five years of marketing exclusivity in addition to the standard five years provided for a new chemical entity under the HatchWaxman Act. These drugs are also eligible for priority review by the U.S. FDA, which reduces the time to market by four months. Drugs with QIDP status also receive fast track status. These initiatives have encouraged innovators to engage in the discovery of new drugs, and various drugs have been swiftly approved since the implementation of these policies. Such favorable government policies have boosted the global tetracycline drugs market in the North America.

The global tetracycline drugs market in Europe is also expected to record growth during the forecast period. The Innovative Medicine Initiative (IMI) in partnership with the European Union and the pharmaceutical industry in Europe is aimed at developing innovative therapeutic alternatives. New Drugs 4 Bad Bugs (ND4BB), an initiative undertaken by the IMI, is a series of programs which would help in public-private collaborations for new drug development. Three programs have been launched successfully through the ND4BB initiative. The market in Latin America and Middle East & Africa is also anticipated to grow during the forecast period owing to high prevalence of infectious diseases in these regions.

Key players operating in the global tetracycline drugs market are Pfizer, Inc., Galderma S.A., Lupin Pharmaceuticals, Inc., Novartis AG, Teva Pharmaceutical Industries Limited, Aptalis, and Medicis Pharmaceutical Corporation, among others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Tetracycline Drugs Market

Pre Book